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Abstract
The study focuses on the mechanisms of endothelial dysfunction in the uremic milieu. Subcutaneous resistance arteries
from 35 end-stage renal disease (ESRD) patients and 28 matched controls were studied ex-vivo. Basal and receptor-
dependent effects of endothelium-derived factors, expression of endothelial NO synthase (eNOS), prerequisites for
myoendothelial gap junctions (MEGJ), and associations between endothelium-dependent responses and plasma levels of
endothelial dysfunction markers were assessed. The contribution of endothelium-derived hyperpolarizing factor (EDHF) to
endothelium-dependent relaxation was impaired in uremic arteries after stimulation with bradykinin, but not acetylcholine,
reflecting the agonist-specific differences. Diminished vasodilator influences of the endothelium on basal tone and
enhanced plasma levels of asymmetrical dimethyl L-arginine (ADMA) suggest impairment in NO-mediated regulation of
uremic arteries. eNOS expression and contribution of MEGJs to EDHF type responses were unaltered. Plasma levels of ADMA
were negatively associated with endothelium-dependent responses in uremic arteries. Preserved responses of smooth
muscle to pinacidil and NO-donor indicate alterations within the endothelium and tolerance of vasodilator mechanisms to
the uremic retention products at the level of smooth muscle. We conclude that both EDHF and NO pathways that control
resistance artery tone are impaired in the uremic milieu. For the first time, we validate the alterations in EDHF type
responses linked to kinin receptors in ESRD patients. The association between plasma ADMA concentrations and endothelial
function in uremic resistance vasculature may have diagnostic and future therapeutic implications.
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Introduction
Adverse cardiovascular events are common complications of
end-stage renal disease (ESRD) and these patients are more likely
to die from cardiovascular disease (CVD) than from kidney failure
[1]. Although the underlying mechanisms that predispose ESRD
patients to higher risk of CVD are incompletely understood,
morphological and functional abnormalities of the endothelium
may play an important role [2]. Endothelial dysfunction is
considered an early marker of CVD [3], which facilitates the
progress of atherosclerosis [4] and contributes to the development
of hypertension through the enhancement of vascular resistance
[5]. Thus, studies aimed to at investigating the mechanisms of
endothelial dysfunction in ESRD are of importance and may
provide a means to ameliorate cardiovascular complications and
introduce novel treatment strategies.
Our current knowledge of endothelial dysfunction in ESRD is
mainly based on findings from animal models [6], circulating
plasma markers [7] and in-vivo assessments in the human forearm
[8]. Although few attempts have been made to estimate
endothelial function in resistance arteries of ESRD patients [9–
11], the mechanisms of endothelial dysfunction need further
clarification. NO deficiency has been considered as a principal
event leading to endothelial dysfunction in the uremic milieu [12].
However, the contribution of NO to endothelium-dependent
control of vascular tone is inversely associated with caliber of
arteries. Another vasodilator, known as endothelium-derived
hyperpolarizing factor (EDHF), seems to act as a predominant
mediator of endothelium-dependent dilatation in resistance-size
arteries. EDHF type responses are characterized by endothelium-
dependent hyperpolarization that occurs due to direct electrical
coupling via myoendothelial gap junctions (MEGJs) and/or the
release of different mediators [13]. The role of EDHF in
endothelial maintenance has been introduced as a back-up
mechanism during NO deficiency. However when deprivation of
EDHF occurs, this may further aggravate endothelial dysfunction
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target organs [13].
Studies concerning the detailed mechanisms of endothelial
dysfunction in resistance arteries with a focus on the relative
contribution of NO and EDHF in ESRD are scarce. Current data
on the contribution of EDHF to endothelium-dependent relaxa-
tion of resistance arteries in kidney failure are mainly based on
animal studies and characterized by explicit heterogeneity [6,14–
18]. To the best of our knowledge, the only study that has
investigated the relative contribution of EDHF vs. NO to
acetylcholine (ACh)-induced-relaxation in ESRD patients has
reported an impairment in NO-mediated responses but an
unchanged, or even increased, role of EDHF as assessed by
forearm blood flow [19].
In this study, we hypothesized that endothelial dysfunction in
resistance arteries of incident dialysis patients is not only restricted
to impairment in production and/or bioavailability of NO, but
EDHF type responses may also be affected by uremic milieu. To
test this hypothesis we isolated arteries from subcutaneous fat to
segregate pharmacologically the relative impairments in NO and
EDHF type responses that confer endothelial dysfunction in
ESRD. Targeted pathways of endothelial dysfunction were
assessed using basal and receptor-dependent stimulation of
endothelium-derived vasodilators, expression of endothelial NO
synthase (eNOS), prerequisites for MEGJ, and associations
between endothelium-dependent responses and plasma levels of
endothelial dysfunction surrogate markers.
Results
Participants
Age, gender, and smoking status were similar between the
groups. The body mass index was lower in ESRD patients vs.
controls. Plasma levels of asymmetrical dimethyl L-arginine
(ADMA), soluble vascular cell adhesion molecule-1 (sVCAM-1),
interleukin-6, pentraxin-3, high sensitivity C-reactive protein
(hsCRP) and lipoprotein(a) and triglycerides were elevated in
ESRD. No differences in blood pressure or total cholesterol were
observed between the groups (Table 1).
Vascular function
In total, 84 subcutaneous arteries with internal diameter of
20966 mm were dissected from 35 ESRD patients and 71 arteries
with internal diameter of 22467 mm were dissected from 28
controls (P.0.05). There was no difference in the magnitude of
pre-constriction 3 mmol/L norepinephrine between the groups
(2.560.2 mN/mm
2 ESRD vs. 2.760.2 mN/mm
2 controls).
Endothelium-dependent relaxation
In controls, ACh and bradykinin (BK) caused relaxation of
arteries with similar magnitude (Figure 1). However, arteries were
more sensitive to BK vs. ACh (pEC50, here and in the following
text: BK 7.960.1 vs. ACh 7.760.1, P=0.01). NOS/cyclooxygen-
ase (COX) inhibition reduced endothelium-dependent relaxation
(Figure 1) and the sensitivity to agonists became similar (ACh:
7.260.1 vs. BK: 7.360.1, P=0.5).
Relaxation and sensitivity to both agonists was attenuated in
ESRD vs. controls (Figure 1). In contrast to the controls, the
sensitivities of ESRD arteries in PSS were similar between the
agonists (ACh: 7.360.1 vs. BK: 7.460.1, P=0.2).
After NOS/COX inhibition relaxation and sensitivity to ACh
and BK were attenuated in ESRD (Figure 1). The concentration-
response curves after NOS/COX inhibition were shifted to the
right in ESRD vs. controls (Figure 1). However, the maximal
EDHF type relaxation was reduced in ESRD vs. controls in
response to BK but not to ACh (BK: P=0.003; ACh: P=0.09).
Moreover, the relative contribution of EDHF was reduced in
ESRD vs. controls in response to BK but not to ACh (Figure 2).
An inhibitor of gap junctions (18-a-glycyrrhetinic acid, 18-aGA)
markedly reduced EDHF type relaxation in response to both
agonists (Figure 1). There was no difference in residual relaxation
after incubation with 18-aGA along with NOS inhibitor, N
v-nitro-
L-arginine-methyl ester (L-NAME) and COX inhibitor, indo-
methacin (Indo) between ESRD vs. controls (Figure 1). The
relative contribution of MEGJs to EDHF type responses was
similar between ESRD and controls independently of the agonist
used (ACh, 1 mmol/l: 8664 ESRD (n=16) vs. 8066 controls
(n=12), P=0.7; BK, 1 mmol/l: 8565 ESRD (n=13) vs. 8763
controls (n=8), P=0.9).
In order to eliminate the possible interference of co-morbidities,
the responses to agonists before and after NOS/COX inhibition in
ESRD patients without diabetes mellitus (DM) and CVD were
compared with those of controls. In response to BK we observed
similar results as above (Figure 1B). In contrast to the whole ESRD
group, in arteries from ESRD without DM and CVD, ACh-
induced relaxation was reduced in PSS as compared to controls
but similar after NOS/COX inhibition (ACh after NOS/COX
inhibition: 760.1 ESRD without DM and CVD (n=18) vs.
7.260.1 controls (n=23), P=0.1).
Table 1. Baseline characteristics of ESRD patients and
controls.
Parameters ESRD (n=35)
Controls
(n=28)
Age (years) 57613 54614
Males n (%) 24 (69) 21 (75)
Body mass index (kg/m
2) 24.163.3* 27.663.7
Systolic blood pressure (mmHg) 144621 138617
Diastolic blood pressure (mmHg) 86611 84611
Total cholesterol (mmol/L) 4.661.2* 5.161.0
Triglycerides (mmol/L) 1.6* (0.8–5.7) 1.3 (0.7–19)
Lipoprotein(a) (mg/L) 409 (50–2572)* 156 (50–802)
S-albumin (g/L) 34.963.4* 38.463.4
S-Creatinine (mmol/L) 620 (249–1069)* 78 (55–100)
Interleukin-6 (pg/ml) 5.0 (1.9–16.8)* 1.5 (0.4–17.1)
hsC-reactive protein (mg/L) 1.9 (0.2–24.9)* 1.4 (0.4–13.9)
Pentraxin-3 (ng/ml) 1.2 (0.5–8.3)* 0.6 (0.1–2.3)
Fibrinogen (g/L) 4.861.3* 3.261.3
Glomerular filtration rate (ml/min) 1263* 8963
Asymmetric Dimethylarginine (mmol/L) 0.660.1* 0.560.1
Soluble VCAM-1 (ng/ml) 1295 (637–1980)* 588 (368–830)
Soluble ICAM-1 (ng/ml) 223 (138–404) 231 (161–363)
Diabetes mellitus n, (%) 10 (29) 0
CVD, n, (%) 13 (37) 0
Antihypertensive treatment, n, (%) 33 (94) 0
Statin treatment, n, (%) 15 (43) 0
*, P,0.05.
doi:10.1371/journal.pone.0036056.t001
Resistance Arteries in ESRD
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Analysis of TEM images focused on morphological prerequisites
for the gap junctions between EC and smooth muscle cells (SMC)
in arteries from ESRD patients and controls (n=3). The main
criteria for identification of MEGJs was the presence of the
characteristic pentalaminar membrane structure at points of cell to
cell contact, where the central region had a higher electron opacity
than the inner parts and distance between the EC and SMC
plasma membranes was around 3.5 nm [20]. TEM images showed
the presence of long protrusions (up to 4.5 mm) from both ECs
(Figure 3A) and SMCs (Figure 3B) penetrating the internal elastic
lamina and forming close contacts with each other (Figure 3C and
3D). Although the observed EC-SMC contacts did not fulfill all
criteria for the characteristic pentalaminar structures, they could
be considered as prerequisites for MEGJs.
Endothelium-independent relaxation
Endothelium-independent relaxation to NO donor sodium
nitroprusside (SNP) was similar between the groups (pEC50:
6.060.1 ESRD (n=17) vs. 6.260.2 controls (n=13), P=0.6). In
ESRD patients pinacidil-induced responses were blunted as
compared to controls (6.160.1 ESRD vs 5.760.1 controls,
P=0.01, Figure 4). NOS/COX inhibition attenuated the response
in controls but not in ESRD (6.160.1 PSS vs 5.860.1 L-
Figure 1. Concentration response curves to acetylcholine (ACh, A) and bradykinin (BK, B). Responses in physiological salt solution (PSS)
and after incubation with N
v-nitro-L-arginine methyl ester plus indomethacin alone (L-NAME+Indo) or together with 18a-glycyrrhetinic acid (L-
NAME+Indo+18a-GA) in arteries from ESRD patients (n=32 for ACh and n=22 for BK) and controls (n=23 for ACh and n=17 for BK). * ESRD vs.
controls, P,0.05.
doi:10.1371/journal.pone.0036056.g001
Figure 2. The relative contribution of endothelium-derived
hyperpolarizing factor (EDHF). Contribution of EDHF in arteries
from ESRD patients and controls in response to acetylcholine (ACh) and
bradykinin (BK). * ESRD vs. controls, P,0.05.
doi:10.1371/journal.pone.0036056.g002
Figure 3. Transmission electron images of arteries from ESRD
patients. The lower magnification pictures (A,B) show an overview of
the vascular wall with endothelium (End) and smooth muscle (SM)
being separated by the internal elastic lamina (IEL). The areas denoted
by the boxes are magnified and show the sites of intercellular contacts
that could be considered as prerequisites of myoendothelial gap
junctions (C, D). The width of the gap is ,20 nm (C, arrow), ,11 nm (D,
arrow). Bar: (A) 2 mm; (B) 3 mm; (C) 0.1 mm; (D) 0,2 mm.
doi:10.1371/journal.pone.0036056.g003
Resistance Arteries in ESRD
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ESRD, respectively, Figure 4). There was no difference between
ESRD and controls in their responses to pinacidil after NOS/
COX inhibition (Figure 4).
Influence of the endothelium-derived factors on basal
tone and expression of eNOS
NOS/COX inhibitors induced constriction of arteries from
both ESRD and control groups. This constriction was reduced in
ESRD vs. controls (Figure 5). Exclusion of the patients with DM
and CVD from ESRD group did not change the outcome
(Figure 5; 0.2860.1 mN/mm
2 ESRD without DM and CVD
(n=17) vs. 0.5960.1 mN/mm
2 controls (n=26), P=0.02). There
was no difference in eNOS expression in ESRD vs. controls
(Figure 6).
Associations between endothelium-dependent
responses and plasma markers of endothelial
dysfunction
The sensitivity of arteries to ACh and BK was negatively
associated with plasma levels of ADMA in ESRD (Figure 7A) but
not in controls (Figure 7B). There was no association between
ADMA and vascular sensitivity to the endothelium-dependent
agonists after NOS/COX inhibition in both groups. Similarly,
sensitivity to SNP was not associated with ADMA levels (data not
shown).
In contrast to the agonists-induced relaxation, constriction in
response to NOS/COX inhibition was negatively associated with
plasma levels of ADMA in both ESRD and controls (Figure 7C
and 7D).
No relation was found between resistance artery function and
other surrogate markers of endothelial dysfunction (soluble
intercellular adhesion molecule-1 (sICAM-1) and sVCAM-1) in
ESRD and controls (data not shown).
Discussion
In this ex-vivo study of human uremic resistance arteries we
describe, for the first time, the relative role of endothelium-derived
factors, agonist-specific differences and associations between
endothelial function and surrogate plasma markers of endothelial
dysfunction. We show that reduced EDHF type responses
contribute markedly to endothelial dysfunction in ESRD.
Impaired EDHF type responses in ESRD were detected with
endothelium-dependent agonist BK but not ACh. Thus, we
suggest that changes in signal transduction from endothelial
receptors towards generation and/or transformation of hyperpo-
larization to the smooth muscle are differently affected by uremic
toxins with a predominant impact on those mediated by kinin
receptors. Diminished vasodilator influence of the endothelium on
basal tone of SMCs along with enhanced plasma levels of ADMA
indicates an impairment in NO-mediated control of arterial tone
in ESRD. While the eNOS expression and the contribution of
Figure 4. Concentration response curves to pinacidil. Responses
in arteries from ESRD patients (n=10) and controls (n=7) in
physiological salt solution (PSS) and after incubation with N
v-nitro-L-
arginine methyl ester plus indomethacin (L-NAME+Indo). * ESRD vs.
controls, P,0.05;
# before vs. after incubation with L-NAME+Indo,
P,0.05.
doi:10.1371/journal.pone.0036056.g004
Figure 5. Contractile response to NOS/COX inhibitors of
arteries from controls (n=26) vs. ESRD patients with (n=32).
*, P,0.05 ESRD vs. controls.
doi:10.1371/journal.pone.0036056.g005
Figure 6. Endothelial nitric oxide synthase (eNOS) expression
in arteries from controls (n=6) and ESRD patients (n=10).
doi:10.1371/journal.pone.0036056.g006
Resistance Arteries in ESRD
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uremic arteries, the upstream machinery of both endothelial
pathways (i.e. NO and EDHF) were impaired. Since relaxation in
response to NO donor or hyperpolarizing agent pinacidil (after
NOS/COX inhibition) were similar between the groups, we
confirm that the endothelium is the main target of uremic
environment, whereas functional capacity of the vascular smooth
muscle appeared to be rather tolerant. In accordance with our
previous study [11] we corroborate a central role of the uremic
milieu in the genesis of endothelial dysfunction. The present study
also shows that among measured plasma markers of endothelial
dysfunction only ADMA was strongly associated with the
magnitude of endothelial dysfunction in uremic resistance arteries.
Thus, our findings provide novel insights into the mechanisms of
endothelial dysfunction in resistance circulation of ESRD patients.
The pattern of impairment of EDHF type responses after BK
but not ACh stimulation in uremic arteries emphasizes the agonist-
specific mechanisms of endothelial dysfunction in this toxic milieu.
We speculate that conventional and/or disease-specific risk factors
may differently affect kinin and muscarinic receptors and/or their
regulatory pathways. For example, endothelial dysfunction in
atherosclerosis appears to be receptor-specific, involving the
muscarinic receptors with relative sparing of the kinin receptor
pathways. Abnormal reactivity of epicardial coronary arteries
during physiologic stress is better represented by BK and not by
ACh responses [21]. Moreover, differences exist between BK- and
ACh- induced relaxation of the mesenteric arteries from
spontaneously hypertensive rats at different ages, suggesting a
more detrimental effect of increased blood pressure on BK-
induced vasorelaxation [22], while selective impairement of
endothelium-dependent relaxation to ACh but not BK is observed
in isolated small omental arteries from women with preeclampsia
[23]. Thus, prior conclusions based only on the vascular effects of
one agonist (i.e. ACh) should be considered with caution. In
contrast to previous studies, in which only ACh was tested [9–10],
our more comprehensive analysis of pathways involved in
endothelial dysfunction of resistance arteries in ESRD patients
revealed an impairment of EDHF contribution coupled with
stimulation of kinin receptors.
Figure 7. Spearman rank correlation between plasma levels of asymmetrical dimethyl L-arginine (ADMA, mmol/L) and artery
sensitivity to endothelium-dependent vasodilators (pEC50, A, B) or vasoconstriction in response to NOS/COX inhibition (L-
NAME+Indo, C, D) in ESRD patients (A, C) and controls (B, D).
doi:10.1371/journal.pone.0036056.g007
Resistance Arteries in ESRD
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EDHF type responses in preeclampsia [24–25], the present data
revealed MEGJs as a common pathway of EDHF in both groups.
Hence, the compensatory response for preservation of endothelial
function via the flexibility of mechanisms behind EDHF type
responses seems to be lacking in ESRD. Since the contribution of
EDHF and MEGJ to ACh-induced relaxation was similar between
the two experimental groups, it is unlikely that impairment at the
level of MEGJs could be linked with kinin receptors. Therefore, it
can be speculated that alterations in BK-induced EDHF type
responses in uremic resistance arteries may reside in the signaling
sequence extending from B2-kinin receptors to the activation of
Ca
2+-dependent K
+-channels (Kca-channels) generating hyperpo-
larization of the endothelium with following transformation to the
smooth muscle via MEGJ. Further studies are warranted to clarify
the involvement of particular endothelial Kca-channels in
alterations of BK-induced EDHF type responses in this patient
group.
Despite the fact that EDHF normally does not act through the
KATP-channels [13], pinacidil-induced responses allowed us to
assess the general mechanism of relaxation induced by hyperpo-
larization due to outward K
+ currents at the level of the smooth
muscle [26]. Moreover, an animal study of renal failure suggested
that alterations in smooth muscle K
+-channels could be involved
in reduced endothelium-dependent hyperpolarization [16]. In our
study, relaxation to pinacidil was reduced in ESRD vs. controls but
this difference disappeared after NOS/COX inhibition, which
opposes the findings in the animal study [16]. Most likely basal
NO had a potentiating effect on pinacidil-induced relaxation in
controls but not in ESRD patients. While in general relaxation
induced by KATP-channels openers has yet been considered
endothelium-independent [27], the potentiating effects of endo-
thelium-derived factors has been reported before [25,28].
Impaired endothelial influence on pinacidil-induced responses
may further support our data about reduced basal release of
endothelium-derived factors in ESRD. Indeed, NOS/COX
inhibitors induced smaller constriction in uremic vs. control
arteries. As basal vascular tone is to a large extend NO-dependent
[29], our data implies a reduction in basal production of NO in
ESRD. In contrast, a previous study reported increased basal NO
production in the forearm of hemodialysis patients [30]. The
inconsistent results may be caused by different methodology, and
selection of patients. Recently, we demonstrated the lack of NO
contribution to shear stress responses in subcutaneous uremic
arteries [11]. In the current study, differences in sensitivity
between BK and ACh, depending from NOS/COX inhibition
in controls but not in ESRD, indicated on distinct NO
contribution to agonist-induced relaxation between the two
groups. Moreover, the negative correlation between serum ADMA
levels and relaxation to ACh and BK in ESRD but not in controls
further supports the impaired contribution of NO to agonists-
induced responses in uremia.
Multiple mechanisms may lead to NO deficiency in renal failure
[12,31]. A decreased bioavailability of NO due to increased pro-
oxidative environment has been suggested [11]. Reduced
expression of eNOS has been linked to a decreased NO
production in an animal model of kidney failure [32]. Studies on
EC cultures have shown that erythrocytes [33] or sera fractions
enriched with advanced glycation end products [34] from uremic
patients may directly affect expression and activity of eNOS.
However, we failed to find any difference in eNOS protein
expression between uremic and control arteries. Moreover, an
elevated vascular expression but unchanged activity of eNOS was
demonstrated in radial arteries of ESRD patients [35]. Neverthe-
less, such observations might indicate that unchanged or even
increased expression of eNOS in the vascular wall could not
guarantee a sufficient NO bioavailability in ESRD patients. We
therefore speculate that endothelial dysfunction along with
unchanged expression of eNOS, may represent a potential
outcome of a reduced ability of the enzyme to generate NO via
eNOS uncoupling with following decrease in NO bioavailability in
uremic resistance arteries.
ADMA may serve as a feasible candidate to link the uremic
environment with endothelial dysfunction in the resistance
vasculature. Indeed, ADMA, as an endogenous inhibitor of eNOS
that accumulates when renal function declines [36], it has been
shown to induce eNOS uncoupling either via substrate reduction
or via direct effect on eNOS catalysis and, as a consequence,
eNOS will generate superoxide radicals instead of NO [37]. On
the other hand, we cannot exclude the possibility that the effect of
ADMA on endothelial superoxide generation may be due to the
activation of other enzymatic sources of superoxide radicals such
as NADPH oxidases. ADMA may also stimulate renin angiotensin
system, and ADMA induced impairement of NO-mediated
function due to increased superoxide production has been shown
to occur via activation of of Ang II-NADPH oxidase pathway in
isolated small vessels from rats [38]. In animal models of
experimental diabetic nephropathy, AngII induced activation of
NADPH oxidase and eNOS uncoupling serves as the major source
of superoxide, and the blockade of AngII signaling ameliorates
eNOS uncoupling by increased tetrahydrobiopterin levels with
following restoration of NO bioavailability and improved
glomerular hemodynamics [39–40].
Although, an association between elevated ADMA levels and
endothelium-dependent dilatation in the forearm was previously
reported [41], we are the first to show an association between
ADMA and endothelium-dependent relaxation in uremic resis-
tance vasculature. The inverse correlation between ADMA and
changes in basal tone after NOS/COX inhibition in both
experimental groups support in-vivo results demonstrating that
ADMA increases vascular resistance in ESRD patients [42] and in
healthy humans [43]. Taken together our data endorse the
proposal that elevated ADMA may act as a potential mechanism
behind the impaired NO-dependent control of uremic resistance
artery tone.
On the other hand, adhesion molecules sICAM-1 and sVCAM-
1, two purported biomarkers of endothelial dysfunction, did not
correlate with changes in basal tone nor with responses to
endothelium-dependent agonists. As ADMA is a potentially
modifiable risk factor, future interventional studies primarily
focusing on acute and long term L-arginine supplementation
[44] or regulation of dimethylarginine dimethylaminohydrolase
activity that confers the intracellular ADMA concentrations [45]
are of interest.
In summary, by studying the mechanisms of endothelial
dysfunction in uremic resistance arteries we were able to dissect
the impairment in basal and agonist-specific effects of two
endothelium-derived vasodilators - EDHF and NO. For the first
time, we provided evidence of impaired EDHF type responses
particularly linked to kinin receptors in ESRD. The current results
support our previous findings that NO plays a critical role in
uremic endothelial dysfunction in resistance circulation. The
observation that preserved responses of smooth muscle to pinacidil
and NO-donor indicated a decisive role of malfunctions within the
endothelium and tolerance of vasodilator mechanisms to the
uremic retention products at the level of smooth muscle. As this
study showed an association between circulating plasma ADMA
concentrations and endothelial dysfunction in uremic resistance
Resistance Arteries in ESRD
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therapeutic implications.
Materials and Methods
Participants
The study was approved by the Ethical Committee at
Karolinska University Hospital and conducted according to the
principles expressed in the Declaration of Helsinki. All participants
involved in the research gave written informed consent prior to
enrollment.
Subcutaneous fat biopsies were obtained from 35 ESRD
patients at the time of peritoneal dialysis catheter insertion. Only
patients starting dialysis treatment were included. Exclusion
criteria were acute infection, vasculitis or liver disease at the time
of evaluation. Control tissue was obtained from 28 age-matched
volunteers without renal, mental or diabetic disease who
underwent hernia repair (n=17) or laparoscopic cholecystectomy
(n=11).
Baseline Laboratory and Clinical Assessments
Clinical history of CVD or DM was obtained from medical
records. CVD was defined as the presence of ischemic cardiac
disease, peripheral vascular disease and/or cerebrovascular
disease. Ongoing medication was collected from medical charts.
Glomerular filtration rate was estimated by the mean of
creatinine- and urea clearances in ESRD patients, whereas
cystatin-C estimated glomerular filtration rate in the controls.
Fasting venous blood samples were taken. Plasma and serum were
stored at 270uC pending further analyses. Serum interleukin-6
was measured on an ImmuliteH analyzer (Siemens Medical
Solution Diagnostic, Los Angeles, CA, USA). Serum concentra-
tions of albumin, creatinine, lipids and hsCRP were measured
routinely. ADMA was assessed in serum by ELISA assays (DLD
Diagnostika GMBH, Germany). Concentrations of pentraxin-3,
sICAM-1 and sVCAM-1 were measured in serum (ELISA assays
from R&D systems, USA).
Vascular function
Arteries were isolated and mounted on two stainless steel wires
(25 mm in diameter) in the organ baths of a four-channel wire
myograph (model 610, Danish Myo Technology; Aarhus, Den-
mark) as described previously [25]. Arteries collected from patients
with ESRD we refer as ‘‘uremic arteries’’.
Once a sustained, steady contraction to norepinephrine
(3 mmol/L) was attained, the concentration-response curves to
the endothelium-dependent vasodilators ACh and BK (1 nmol/L
to 3 mmol/L) or SNP (10 nmol/L to 100 mmol/L), NO-donor and
an opener of ATP-sensitive K
+-channels (KATP-channels), pinaci-
dil (10 nmol/L to 100 mmol/L), were obtained. Arteries were then
incubated for 20 min with NOS inhibitor (300 mmol/L) and COX
inhibitor, Indo (10 mmol/L). Subsequently, arteries were pre-
constricted again and second concentration-response curve for
endothelium-dependent agonists was obtained. The term
‘‘EDHF’’ used in this study refers to the L-NAME+Indo-
insensitive component of endothelium-dependent vasodilatation.
The level of increased resting tone of the arteries after incubation
with L-NAME+Indo was considered as an index of vasoactive
properties of the endothelium, reflecting a basal release of
endothelium-derived vasoactive factors. To evaluate the contribu-
tion of gap junctions in EDHF type responses, the concentration-
response curves to ACh and BK were constructed after 15 min co-
incubation with 18-aGA (100 mmol/L) in the presence of L-
NAME+Indo.
Fluorescence immunohistochemistry
Freshly isolated arteries where cryopreserved in optimal cutting
temperature compound on dry ice. Transverse 8 mm cryosections
were prepared and mounted onto slides, air-dried, and stored at
280uC. For immunostaining, cryosections were incubated for
1.5 hr at room temperature with the mouse polyclonal anti-eNOS
antibody (1:250, BD Biosciences 610296). Incubation with the
secondary goat anti-mouse antibody (Invitrogen, Alexa fluor 488
A11001) was done for 1 hr in the dark. Glass coverslips were
mounted with Vectashield H-1200 Mounting Kit (Vector
Laboratories). Stained sections were examined immediately under
fluorescence microscope. All images presented are in (6100)
magnification.
Transmission electron microscopy
Artery segments were fixed as described previously [24–25].
Serial transverse, ultra-thin sections (approximately 50–80 nm)
were cut. The series consisted of 3–5 sections. For each artery such
series were repeated three times after an interval of 10 mm.
Sections were examined in a Tecnai 10 transmission electron
microscope at 80 kV and digital images were captured.
Chemicals
The composition of PSS was (in mmol/L): NaCl 119, KCl 4.7,
CaCl2 2.5, MgSO4 1.17, NaHCO3 25, KH2PO4 1.18, EDTA
0.026, and glucose 5.5. The chemicals were obtained from Sigma,
St. Louis. To prepare stock solution, the substances were dissolved
in distilled water. Indo and pinacidil were dissolved in ethanol and
18a-GA was dissolved in DMSO. Pilot studies showed that the
solvents used had no effect upon vascular responses at their final
concentrations.
Data analysis
In figures, results are expressed as mean 6 SEM. In tables,
normally distributed variables are expressed as mean 6 SD, and
non-normally distributed variables as medians and interquartile
ranges. Baseline characteristics of the patients and arteries used
and staining were analysed by conventional parametric and non-
parametric methods. The isometric force developed by artery
segment during application of vasoactive compounds was
calculated using Myodata (Danish Myo Technology, Denmark)
and expressed as mN/mm
2. Relaxation was expressed as a
percentage of the pre-constriction. In order to visualize the relative
contribution of EDHF or MEGJs, a percentage of the relaxation
was calculated after pre-incubation with L-NAME+Indo or L-
NAME+Indo+18a-GA and related to the full response in PSS or
after pre-incubation with L-NAME+Indo. Negative log concen-
tration (in mol/l) required to achieve 50% of the maximum
response (pEC50) was calculated by nonlinear regression analysis
(BioDataFit 1.02). ANOVA was used to compare concentration-
response curves before and after incubation with different
inhibitors. Spearman’s rank correlation was used to determine
the associations between artery sensitivity (pEC50) to endothelium-
dependent vasodilators and plasma markers of endothelial
dysfunction. Significance was taken at the 5% level for all
comparisons. All statistical analyses were performed with STA-
TISTICA (v.10.0, StatSoft, Uppsala, Sweden).
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